Selected recent publications in high impact journals

Publications in high impact journals

  1. Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapyCancer Biol Ther. 2015 Mar 25:0. [Epub ahead of print] PMID:  25806780
  2.    Kardos GR, Dai MS, Robertson GP. Growth inhibitory effects of large subunit ribosomal proteins in melanoma.  Pigment Cell Melanoma Res. 2014 Sep; 27(5):801-12
  3. Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP. Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Mol Cancer Ther. 2014 Oct;13(10):2328-40. doi: 10.1158/1535-7163.MCT-14-0357. Epub 2014 Jul 31. PMID: 25082958
  4. Kuzu OF, Gowda R, Sharma A, Robertson GP. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport.   Mol Cancer Ther. 2014 Jul;13(7):
  5. Gowda R, Madhunapantula SV, Kuzu OF, Sharma A, Robertson GP. Targeting multiple key signaling pathways in melanoma using leelamineMol Cancer Ther. 2014 Jul;13(7
  6. Mumford, B. S., and Robertson, G. P. Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. (April 2014). Mol Diagn Ther 18, 175-183.
  7. Dluzen, D. F., Sun, D., Salzberg, A. C., Jones, N., Bushey, R. T., Robertson, G. P., and Lazarus, P. Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA  (March 2014). 491-3p. J Pharmacol Exp Ther 348, 465-477.
  8. Gowda R, Jones NR, Banerjee S, Robertson GP. Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol. 2013 Dec;4
  9. Madhunapantula, S. V., Sharma, A., Gowda, R., and Robertson, G. P. Identification of glycogen synthase kinase 3a as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2013 Nov;26(6):886-99. doi: 10.1111/pcmr.12156. Epub 2013 Sep 19. PMID: 24034838, [PubMed - in process]
  10. Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, Huang L.  Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.  Mol Ther. 2013 Oct;21(10):1919-29. doi: 10.1038/mt.2013.135. Epub 2013 Jun 18. PMID: 23774794
  11. Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.  Am J Pathol. 2013 Apr;182(4):1151-62. doi: 10.1016/j.ajpath.2012.12.019. Epub 2013 Feb 12.  PMID: 23416158
  12. Khanna P, Chung CY, Neves RI, Robertson GP, Dong C. CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas. Oncogene. 2013 Jul 22. doi: 10.1038/onc.2013.249. [Epub ahead of print] PMID: 23873025
  13. Michelotti BF, Brooke S, Mesa J, Wilson MZ, Moyer K, Mackay DR, Neves RI, Potochny J.  Analysis of clinically significant seroma formation in breast reconstruction using acellular dermal grafts.  Ann Plast Surg. 2013 Sep;71(3):274-7. doi: 10.1097/SAP.0b013e3182923dc9.  PMID: 23788150
  14. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J.  Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States.  Ann Surg Oncol. 2013 Jun 21. [Epub ahead of print] PMID:  23793364
  15. Singh S, Sharma A, Robertson GP. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res. 2012 Nov 15;72(22):5663-8. doi: 10.1158/0008-5472.CAN-12-1527. Epub 2012 Nov 8. Review. PMID:23139207
  16. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.  Mol Cancer Ther. 2013 Jan;12(1):3-15. doi: 10.1158/1535-7163.MCT-12-0492. Epub 2012 Oct 30.  PMID: 23112250
  17. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GPSelenium-containing histone deacetylase inhibitors for melanoma management.  Cancer Biol Ther. 2012 Jul;13(9):756-65. Epub 2012 Jun 6.  PMID: 22669577
  18. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GPTargeting sphingosine kinase-1 to inhibit melanoma.  Pigment Cell Melanoma Res
  19. Madhunapantula SV, Mosca PJ, Robertson GPThe Akt signaling pathway: an emerging therapeutic target in malignant melanoma.  Cancer Biol Ther. 2011 Dec 15;12(12):1032-49. doi: 10.4161/cbt.12.12.18442. Epub 2011 Dec 15. Review.  PMID:  22157148
  20. Sharma A, Madhunapantula SV, Robertson GPToxicological considerations when creating nanoparticle-based drugs and drug delivery systems.  Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):47-69. doi: 10.1517/17425255.2012.637916. Epub 2011 Nov 19. Review. PMID:22097965
  21. Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ.  Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.  Cancer Biol Ther. 2010 Dec 1;10(11):1091-7. Epub 2010 Dec 1.  PMID: 20930514
  22. Rezze GG, Leon A, Silva DC, Neves RI, Molina GC, Carraro DM, Landman G, Duprat JP.  Primary cutaneous melanoma arising in agminated melanocytic nevi: CDKN2A and CDK4 mutation screening.  Acta Derm Venereol. 2012 Jan;92
  23. Clarke LE, Frauenhoffer E, Fox E, Neves R, Bruggeman RD, Helm KF. Cd10-positive myxofibrosarcomas: A pitfall in the differential diagnosis of atypical fibroxanthoma. J Cutan Pathol;37(7):737-743. [More]
  24. Desai D, Madhunapantula SV, Gowdahalli K, Sharma A, Chandagaludoreswamy R, El-Bayoumy K, Robertson GP, Amin S. Synthesis and characterization of a novel inos/akt inhibitor se,se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (pbise)--against colon cancer. Bioorg Med Chem Lett;20(6):2038-2043.
  25. Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ. Unsuccessful high dose il-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biol Ther;10(11).
  26. Huh SJ, Chung CY, Sharma A, Robertson GP. Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol;176(6):2948-2957. [more...]
  27. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res;70(14):6071-6082. [more..]
  28. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the mapk pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol;80(5):624-637. [more...]
  29. Madhunapantula SV, Gowda R, Inamdar GS, Robertson GP. In situ photoimmunotherapy: A new hope for cutaneous melanoma patients. Cancer Biol Ther;10(11). [more..]
  30. Madhunapantula SV, Mosca P, Robertson GP. Steroid hormones drive cancer development. Cancer Biol Ther;10(8).
  31. Mathew R, Jia W, Sharma A, Zhao Y, Clarke LE, Cheng X, Wang H, Salli U, Vrana KE, Robertson GP, et al. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J;24(8):2702-2715.
  32. Nguyen N, Sharma A, Sharma AK, Desai D, Huh SJ, Amin S, Meyers C, Robertson GP. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila).[more..]
  33. Wood L, Fountaine TJ, Rosamilia L, Helm KF, Clarke LE. Cutaneous cd34+ spindle cell neoplasms: Histopathologic features distinguish spindle cell lipoma, solitary fibrous tumor, and dermatofibrosarcoma protuberans. Am J Dermatopathol;32(8):764-768.[more...]
  34. Zhang P, Ozdemir T, Chung CY, Robertson GP, Dong C. Sequential binding of alpha(v)beta3 and icam-1 determines fibrin-mediated melanoma capture and stable adhesion to cd11b/cd18 on neutrophils. J Immunol;186(1):242-254.
  35. Huh SJ, Chen Y, Friedman SL, Huang H-J, Cavenee WK, Robertson GP. KLF 6 Gene and early Melanoma development in collagen I-rich extracellular. Journal of the National Cancer Institute, 2010 Aug 4;102(15): 1131-47 [more]
  36. de Sá BC, Fugimori ML, Ribeiro Kde C, Duprat Neto JP, Neves RI, Landman G. Proteins involved in pRb and p53 pathways are differentially expressed in thick and superficial spreading melanomas. Res. 2009Jun;19(3):135-41.PMID: 19369901[more]
  37. Madhunapantula SV, Robertson GP. The PTEN-AKT3 Signaling Cascade as a Therapeutic Target in Melanoma. Pigment Cell Melanoma Res 2009. [more]
  38. Clarke LE, Fountaine TJ, Hennessy J, Bruggeman RD, Clarke JT, Mauger DT, Helm KF. Cutan Pathol Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi. 2009 Apr;36(4):433-8.PMID: 19278428 (PubMed - indexed for MEDLINE) [more]
  39. Tran MA, Watts RJ, Robertson GP. Use of Liposomes as Drug Delivery Vehicles for Treatment of Melanoma. Pigment Cell Melanoma Res 2009. [more]
  40. Gaitonde S, De SK, Tcherpakov M, Dewing A, Yuan H, Riel-Mehan M, Krajewski S, Robertson G, Pellecchia M, Ronai Z. BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res 2009; 22(2):187-95.[more]
  41. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP. Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clin Cancer Res 2009; 15(5):1674-1685.
  42. Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoglu EI, Tabakovic A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett 2008; 8(12):4116-21
  43. Helm TN, Helm KF. Arch Dermatol More evidence for a new melanoma paradigm. 2008 Jul;144(7):946-7 PMID: 18645152. [more]
  44. Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh S-J, Robertson GP, Amin S. Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J. Med. Chem. 2008 Dec 25; 51(24):7820-6. PMCID: PMC2629797 [Available on 2009/12/25]
  45. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008 Sept; 68(18): 7638-49.
  46. Salli U, Fox TE, Carkaci-Salli N, Sharma A, Robertson GP, Kester M et al. Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells Dev 2008. [more]
  47. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008; 68(9):3429-39. PMCID: PMC2603082.
  48. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal cerammide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical Cancer Research 2008; 14 (11): 3571-81.
  49. Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP. PBISe, A Novel Selenium Containing Drug for Treatment of Malignant Melanoma. Molecular Cancer Therapeutics 2008;7(5):1297-308.[more